Brief: Alpha Tau Announces Completion Of Enrollment Of Japanese Pivotal Clinical Trial In Recurrent Head & Neck Cancer
03/01/2022 12:25
Jan 3 (Reuters) - Healthcare Capital Corp HCCC.O :
* ALPHA TAU ANNOUNCES COMPLETION OF ENROLLMENT OF JAPANESE
PIVOTAL
CLINICAL TRIAL IN RECURRENT HEAD & NECK CANCER
Source text for Eikon: ID:nPn4Xmx4La
Further company coverage: HCCC.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer